Ovarian cancer is
highly aggressive and has high rates of recurrence
and metastasis. Due to the limited effects of current treatments,
it is necessary to conduct research and develop new treatment options.
The application of gene therapy in tumor therapy is gradually increasing
and has exciting prospects. MicroRNA-7 (miR-7) has been reported to
inhibit the growth, invasion, and metastasis of a variety of solid
tumors. Cationic liposomes are safe and effective gene delivery systems
for transfection in vivo and in vitro. To realize the application
of miR-7 in the treatment of ovarian cancer, cationic liposomes were
prepared with 1,2-dioleoyl-3-trimethylammonium-propane, 1,2-dioleoyl-
sn
-glycero-3-phosphoethanolamine, and cholesterol. The miR-7
liposomes had a suitable particle size, potential, and a high cellular
uptake rate. MiR-7 encapsulated by liposomes could be effectively
delivered to ovarian cancer cells and successfully targeted to the
tumor site in a mouse xenograft model of ovarian cancer. In vitro
and in vivo experiments revealed that the miR-7 liposomes had a significant
ability to inhibit the growth, invasion, and migration of ovarian
cancer, probably by inhibiting the expression of the epidermal growth
factor receptor. Our studies of miR-7 liposomes demonstrated a safe
and efficient microRNA delivery system for the gene therapy of ovarian
cancer.